Prostatype Genomics AB (OSTO:PROGEN) Moat Score: 0/10 (As of Jul. 02, 2026)


OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
25 GF Score
Price kr0.40
GF Value kr0.11
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Moat Score?

Prostatype Genomics AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Prostatype Genomics AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Prostatype Genomics AB might have No Moat - No discernible moat.

Prostatype Genomics AB  (OSTO:PROGEN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Prostatype Genomics AB Moat Score Related Terms

OSTO:PROGEN
25GF Score
Prostatype Genomics AB OSTO:PROGEN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.40 is trading 260.9% above its estimated GF Value™ of kr0.11. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Moat Score: 0
  • GF Value™: kr0.11 vs. price of kr0.40 (260.9% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for OSTO:PROGEN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.40
Price
kr0.11
GF Value